Further results enactment to the usage of a trial that identifies which patients with signifier II-IV resectable colorectal cancer are apt to payment from adjuvant chemotherapy.
The Signatera assay, manufactured by Natera Inc., measures circulatory tumor DNA (ctDNA) to measure molecular residual illness (MRD) astatine 4 weeks aft surgery.
New results from the GALAXY survey amusement that patients who were MRD-positive 4 weeks aft country (18%) had important payment from receiving adjuvant chemotherapy, but conversely, those who were MRD-negative patients (82%) did not.
"There was nary important payment for MRD-negative patients who received chemotherapy," commented Alexey Aleshin, MD, MBA, main aesculapian serviceman astatine Natera. "This is beauteous profound and, possibly successful time, ctDNA treatment-guided approaches volition find who receives oregon doesn't person adjuvant therapy."
The existent information builds connected results from the aforesaid survey antecedently presented astatine the 2022 ASCO Gastrointestinal Cancers Symposium (GICS), which were reported by Medscape Medical News astatine the time. Then, the median follow-up clip was 11.4 months.
The existent insubstantial presents findings from an extended follow-up clip up to 16.7 months and disease-free endurance (DFS) appraisal astatine 18 months.
The survey was published online today successful Nature Medicine.
Future Standard of Care?
Signatera is already successful objective usage successful the United States (where it was launched successful 2019). "It is covered by Medicare and reimbursement is already successful spot for testing," Aleshin said.
More than a 4th of oncologists who spot this diligent colonisation are already administering the test, helium told Medscape Medical News. "About 90% of patients person early-stage disease, and we haven't had immoderate caller innovation successful that space. One of the test's biggest uses is successful monitoring patients with early-stage illness to drawback aboriginal recurrence."
He noted that the trial whitethorn besides beryllium utile for monitoring attraction effect successful patients treated with immunotherapy. "It's hard to spot with imaging if a diligent is responding to immunotherapy, and ctDNA performs overmuch amended for this purpose," helium said.
Aleshin's idiosyncratic content is that the trial volition yet go the modular of care. "We person results from different smaller studies, but to alteration however crab is managed requires results from larger cohorts," helium said.
Extended Follow-Up
The existent survey describes results from the GALAXY limb of the ongoing CIRCULATE-Japan trial, which according to the authors, is 1 of the largest and astir broad prospective studies of MRD investigating successful resectable colorectal cancer.
Led by Takayuki Yoshino, MD, of the National Cancer Center Hospital East successful Kashiwa, Japan, the extremity of the survey was to prospectively validate and physique upon the antecedently published evidence. The researchers sought to amusement that postsurgical ctDNA positivity (MRD timepoint) is prognostic of illness recurrence successful early-stage colorectal cancer, and they besides looked astatine the interaction of postsurgical ctDNA connected outcomes, implications for adjuvant chemotherapy selection, and the relation betwixt ctDNA and prognosis.
The cohort included 1039 patients with signifier II-IV resectable colorectal cancer, of whom 18% (187/1039) were ctDNA-positive astatine 4-weeks post-surgery, and 82% (852/1039) were ctDNA-negative.
Among the ctDNA-positive patients, 61.4% experienced recurrence, compared with 9.5% of ctDNA-negative patients (HR, 10.0; P < .0001). This extrapolated to an 18-month DFS of 38.4% vs.90.5%, and this inclination was observed crossed each stages.
Upon multivariate investigation for DFS successful patients with signifier II-III disease, ctDNA positivity astatine 4-weeks post-surgery was the astir important prognostic origin associated with accrued hazard for illness recurrence (HR, 10.82; P < .001) The authors constituent retired that each clinicopathological hazard factors traditionally utilized for staging and prognostication were not significant, and the information besides suggested that ctDNA was much informative compared with carcinoembryonic antigen (CEA) values.
Of the 187 patients who were ctDNA-positive astatine 4 weeks postsurgery, 182 had ctDNA clearance information available. Adjuvant chemotherapy was administered to 92 of those 182, while the remaining 90 were placed successful the reflection arm.
Adjuvant chemotherapy was associated with a higher estimated cumulative incidence of ctDNA clearance of 68.5% (63/92) of patients by 24 weeks vs 12.2% (11/90) of the patients successful the reflection limb (adjusted HR, 8.50; P < .0001). Patients who did not wide ctDNA besides had inferior DFS (P < .0001).
Randomized Data Needed
Approached by Medscape Medical News for an autarkic comment, Thomas J. George Jr, MD, prof of medicine and manager of the GI Oncology Program astatine the University of Florida, Gainesville, noted that this is simply a precise awesome dataset, "and the authors are to beryllium commended for providing the probe assemblage with this information."
"I judge this information further informs our usage of circulating tumor DNA beingness oregon lack pursuing surgical resection of colon cancer arsenic a prognostic marker," helium emphasized. However, helium added that "because the survey was not prospectively randomized to delegate oregon withhold therapy based upon ctDNA trial results, we cannot definitively accidental that ctDNA tin foretell who volition payment from adjuvant therapy."
George explained that these information further validate that patients with MRD-positive illness are astatine precocious hazard for recurrence and those with MRD-negative illness are astatine debased hazard for recurrence. "However, patients astatine precocious hazard for recurrence are precisely those who we already cognize should payment from being offered adjuvant chemotherapy," helium said.
"We inactive request prospective randomized controlled objective trials to determination this accusation to a personalized/precision oncology level of grounds and corroborate that, for the idiosyncratic patient, the determination of ctDNA presumption pursuing country tin foretell whether that idiosyncratic diligent volition oregon volition not payment from adjuvant chemotherapy administration. Fortunately, immoderate of these trials are actively ongoing."
Also weighing successful connected the research, Benjamin Weinberg, MD, subordinate prof of medicine successful the Division of Hematology and Oncology astatine Georgetown University's Lombardi Comprehensive Cancer Center successful Washington, DC, said these information are precise interesting. "While I decidedly usage this successful my practice, I'm not yet comfy [about withholding adjuvant chemotherapy and] observing ctDNA antagonistic patients with signifier III disease, though I bash successful signifier II patients wherever the chemo payment is smaller."
Another caveat is that the proceedings is not randomized, Weinberg added, and immoderate patients had shorter follow-up. "But determination are ongoing prospective randomized studies addressing chemo vs reflection with ctDNA, truthful we volition person much answers," helium said.
The survey was supported by the Japan Agency for Medical Research and Development. Several of the authors study relationships with manufacture arsenic noted successful the paper. George reports that helium serves arsenic a advisor to Pfizer Oncology and Tempus Labs.
Nature Medicine. Published online January 16, 2023. Full text
Roxanne Nelson is simply a registered caregiver and an award-winning aesculapian writer who has written for galore large quality outlets and is simply a regular contributor to Medscape.
For much from Medscape Oncology, articulation america connected Twitter and Facebook
English (US)